Our Science

Our pipeline

Innovation that advances cancer care

Seagen is developing a new generation of targeted, empowered treatments to advance cancer care. We’ve designed our pipeline with patients in mind, focusing on therapies that have the potential to address significant unmet medical needs.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Seagen Overview Pipeline

Program

Phase

Phase

Brentuximab vedotin (ADCETRIS®)

Learn More
Phase 1
Phase 2
Phase 3

R/R Diffuse Large B-Cell Lymphoma

SGN35-31: + lenalidomide, rituximab

1L Hodgkin lymphoma (HL)

SGN35-27: + nivolumab, doxorubicin and dacarbazine

1L HL or PTCL (unfit for combination chemotherapy)

SGN35-15: Monotherapy

R/R HL and PTCL

SGN35-28: Retreatment

R/R HL (pediatrics)

CheckMate 744: + nivolumab

Enfortumab vedotin-ejfv (PADCEV®)

Learn More
Phase 1
Phase 2
Phase 3

1L Locally advanced or metastatic urothelial cancer

EV-302: + pembrolizumab, +/- chemotherapy

Locally advanced or metastatic urothelial cancer*

EV-301: Post PD(L)-1 and post platinum chemotherapy

Locally advanced or metastatic urothelial cancer*

EV-201: Cohort 2 post anti-PD(L)-1 or post PD(L)-1 inhibitor, platinum naïve and cisplatin ineligible

1L/2L Locally advanced or metastatic urothelial or muscle-invasive cancer

EV-103: +/- pembrolizumab or other anti-cancer agents

1L Muscle invasive bladder cancer

EV-303/KEYNOTE-905: + pembrolizumab

1L Muscle invasive bladder cancer

EV-103: +/- pembrolizumab

Locally advanced or metastatic solid tumors

EV-202: Monotherapy

Tucatinib (TUKYSA®)

Learn More
Phase 1
Phase 2
Phase 3

HER2CLIMB-02 –  Metastatic HER2+ breast cancer

HER2CLIMB-02: + T-DM1

R/R HER2+ metastatic colorectal cancer

MOUNTAINEER: + trastuzumab

1L HER2+ gastric cancer

+ trastuzumab, oxaliplatin

Tisotumab vedotin

Learn More
Phase 1
Phase 2
Phase 3

Recurrent or metastatic cervical cancer†‡

innovaTV 204: Monotherapy

1L/2L Recurrent or metastatic cervical cancer

innovaTV 205: + other anti-cancer agents and monotherapy

R/R Metastatic solid tumors

innovaTV 207: Monotherapy

Platinum-resistant ovarian cancer

innovaTV 208: Monotherapy

Ladiratuzumab vedotin

Learn More
Phase 1
Phase 2
Phase 3

1L Metastatic triple-negative breast cancer

+ pembrolizumab

R/R Metastatic breast cancer (HR+/HER2-)

+ trastuzumab

R/R Metastatic solid tumors

Monotherapy

SEA-BCMA

Phase 1
Phase 2
Phase 3

R/R Multiple myeloma

+/- dexamethasone

SEA-CD40

Phase 1
Phase 2
Phase 3

R/R Pancreatic cancer

+/- pembrolizumab, gemcitabine, nap-paclitaxel

SGN-CD228A

Phase 1
Phase 2
Phase 3

R/R Solid tumors

Monotherapy

SEA-CD70

Phase 1
Phase 2
Phase 3

R/R MDS/AML

Monotherapy

SEA-TGT

Phase 1
Phase 2
Phase 3

R/R Solid tumors and lymphoma

+/- pembrolizumab

SGN-B6A

Phase 1
Phase 2
Phase 3

R/R Solid tumors

Monotherapy

SGN-CD30C

Phase 1
Phase 2
Phase 3

Lymphoma

1L=frontline/first-line, 2L=second-line, R/R=relapsed/refractory, PTCL=peripheral T-cell lymphoma.

*Enrollment Complete
Pivotal Trial
Top-line Data Reported

Request additional information

Request additional information about an investigational therapy or report an adverse event.

Contact Medical Information